Abstract
Introduction
Hematopoietic stem cell transplantation (HCT) is considered a standard treatment for high-risk acute myeloid leukemia (AML) in first or second complete remission (CR). Unfortunately, not all patients achieve complete remission prior to HCT. We sought to establish predictive factors for survival after HCT for refractory AML after FLAMSA-RIC.
Patients and methods
We analyzed the outcome of 44 consecutive patients aged between 21 and 65 years transplanted at the University Hospitals of Jena and Leipzig for refractory AML between 2006 and January 2013. Conditioning for HCT was performed with chemotherapy consisting of fludarabine, cytarabine, and amsacrine followed by total body irradiation or busulfan combined with cyclophosphamide. Antithymocyte globulin was given when transplanting from unrelated donors (FLAMSA-RIC).
Results
Estimated overall survival (OS) and event-free survival (EFS) at 3 years after a median follow-up of 34 (range 6–71) months were 15 and 12 %, respectively. Causes of death were relapse in 66 %, infection in 11 %, and graft-versus-host disease (GvHD) in 7 % of all patients. Twenty-five from 42 evaluable patients (60 %) achieved CR 4 weeks after HCT, while eight patients had partial remission (PR), and nine patients had stable disease (SD). Another six patients with PR and SD achieved CR (overall CR rate 74 %) from 4 weeks to day 90 after HCT following reduction in immunosuppression. The strongest favorable factors in univariate analysis for OS, EFS, and RI were ≥98 % total donor chimerism 2–4 weeks after HCT and <3 lines of pretreatment prior to HCT. In addition, better OS was detected in patients with <20 % bone marrow blasts alone (32 vs. 5 % at 3 years) and in combination with <3 lines of pretreatment (38 vs. 4 % at 3 years). Only a trend for better EFS and lower RI was observed in patients with limited chronic GvHD. In addition, a lower RI was seen in patients with <5 % blasts 4 weeks after HCT. Multivariate analysis revealed that ≥98 % donor chimerism 2–4 weeks after HCT for OS, EFS, and RI and <3 lines of pretreatment for OS and EFS are the strongest predictors for better outcome.
Conclusion
FLAMSA-RIC shows long-term survival in refractory AML patients. Factors for favorable outcome are <20 % bone marrow blasts prior to HCT, <3 lines of pretreatment and complete donor chimerism after HCT.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Breems DA, Van Putten WL, Huijgens PC, Ossenkoppele GJ, Verhoef GE, Verdonck LF et al (2005) Prognostic index for adult patients with acute myeloid leukemia in first relapse. J Clin Oncol 23(9):1969–1978
Buchholz S, Dammann E, Stadler M, Krauter J, Beutel G, Trummer A et al (2012) Cytoreductive treatment with clofarabine/Ara-C combined with reduced-intensity conditioning and allogeneic stem cell transplantation in patients with high-risk, relapsed, or refractory acute myeloid leukemia and advanced myelodysplastic syndrome. Eur J Hematol 88(1):52–60. doi:10.1111/j.1600-0609.2011.01703.x
Craddock C, Labopin M, Pillai S, Finke J, Bunjes D, Greinix H et al (2011) Factors predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukaemia. Leukemia 25(5):808–813. doi:10.1038/leu.2011.13
Döhner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK et al (2010) Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 115(3):453–474. doi:10.1182/blood-2009-07-235358
Duval M, Klein JP, He W, Cahn JY, Cairo M, Camitta BM et al (2010) Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. J Clin Oncol 28(23):3730–3738. doi:10.1200/JCO.2010.28.8852
Gray RJ (1988) A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16:1141–1154
Krejci M, Doubek M, Dusek J, Brychtova Y, Racil Z, Navratil M et al (2013) Combination of fludarabine, amsacrine, and cytarabine followed by reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation in patients with high-risk acute myeloid leukemia. Ann Hematol 92(10):1397–1403. doi:10.1007/s00277-013-1790-5
Löwenberg B, Downing JR, Burnett A (1999) Acute myeloid leukemia. N Engl J Med 341(14):1051–1062
Massenkeil G, Nagy M, Lawang M, Rosen O, Genvresse I, Geserick G et al (2003) Reduced intensity conditioning and prophylactic DLI can cure patients with high-risk acute leukaemias if complete donor chimerism can be achieved. Bone Marrow Transplant 31(5):339–345
Oyekunle AA, Kröger N, Zabelina T, Ayuk F, Schieder H, Renges H et al (2006) Allogeneic stem-cell transplantation in patients with refractory acute leukemia: a long-term follow-up. Bone Marrow Transplant 37(1):45–50
Pfeiffer T, Schleuning M, Mayer J, Haude KH, Tischer J, Buchholz S et al (2013) Influence of molecular subgroups on outcome of acute myeloid leukemia with normal karyotype in 141 patients undergoing salvage allogeneic stem cell transplantation in primary induction failure or beyond first relapse. Haematoligca 98(4):518–525. doi:10.3324/haematol.2012.070235
Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al (1995) Consensus on acute GVHD grading. Bone Marrow Transplant 15(6):825–828
Saure C, Schroeder T, Zohren F, Bruns I, Czibere A et al (2012) Upfront allogeneic blood stem cell transplantation for patients with high-risk myelodysplastic syndrome or secondary acute myeloid leukemia using a FLAMSA-based high-dose sequential conditioning regimen. Biol Blood Marrow Transplant 18(3):466–472. doi:10.1016/j.bbmt.2011.09.006
Sayer HG, Kröger M, Beyer J, Kiehl M, Klein SA, Schaefer-Eckart K et al (2003) Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: disease status by marrow blasts is the strongest prognostic factor. Bone Marrow Transplant 31(12):1089–1095
Schmid C, Schleuning M, Ledderose G, Tischer J, Kolb HJ (2005) Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol 23(24):5675–5687
Schmid C, Schleuning M, Schwerdtfeger R, Hertenstein B, Mischak-Weissinger E, Bunjes D et al (2006) Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. Blood 108(3):1092–1099
Schmid C, Labopin M, Nagler A, Bornhäuser M, Finke J, Fassas A et al (2007) Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. J Clin Oncol 25(31):4938–4945
Schmid C, Schleuning M, Hentrich M, Markl GE, Gerbitz A, Tischer J et al (2008) High antileukemic efficacy of an intermediate intensity conditioning regimen for allogeneic stem cell transplantation in patients with high-risk acute myeloid leukemia in first complete remission. BMT 41(8):721–727. doi:10.1038/sj.bmt.1705965
Schmid C, Schleuning M, Tischer J, Holler E, Haude KH, Braess J et al (2012a) Early allo-SCT for AML with a complex aberrant karyotype–results from a prospective pilot study. Bone Marrow Transplant 47(1):46–53. doi:10.1038/bmt.2011.15
Schmid C, Labopin M, Nagler A, Niederwieser D, Castagna L, Tabrizi R et al (2012b) Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation. Blood 119(6):1599–1606. doi:10.1182/blood-2011-08-375840
Schneidawind D, Federmann B, Faul C, Vogel W, Kanz L, Bethge WA (2013) Allogeneic hematopoietic cell transplantation with reduced-intensity conditioning following FLAMSA for primary refractory or relapsed acute myeloid leukemia. Ann Hematol 92(10):1389–1395. doi:10.1007/s00277-013-1774-5
Scrucca L, Santucci A, Aversa F (2007) Competing risk analysis using R: an easy guide for clinicians. Bone Marrow Transplant 40(4):381–387
Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE et al (1980) Chronic graft-versus-host syndrome in man: a long-term clinicopathologic study of 20 Seattle patients. Am J Med 69:204–217
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors have nothing to disclose. There are no competing financial interests in relation to the work described.
Additional information
On behalf of my co-authors, I state that the material is original research, has not been previously published, and has not been submitted for publication elsewhere while under consideration.
Rights and permissions
About this article
Cite this article
Pfrepper, C., Klink, A., Behre, G. et al. Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation. J Cancer Res Clin Oncol 142, 317–324 (2016). https://doi.org/10.1007/s00432-015-2050-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-015-2050-y